Please assess the completion status of the following clinical trial:

Trial Title: Mycophenolate Mofetil for IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between the ages of 18 and 70 years~* Renal biopsy showing a histological diagnosis IgAN, with predominant or codominant mesangial deposition of IgA on immunofluorescent studies~* Daily urinary protein excretion \> 1 g on at least 3 separate occasions~* Serum creatinine \< 400 umol/L~* Patients who are willing to give written informed consent and to participate in and comply with the study protocol~Exclusion Criteria:~* Presence of concomitant glomerular diseases~* Patients with known hypersensitivity to MMF~* Patients receiving treatment with other cytotoxic agents~* Serum creatinine \> 400 umol/L~* Women who are lactating, pregnant or of childbearing potential not using, or who are unwilling to use, a reliable contraceptive method during and for 6 weeks following conclusion of MMF therapy. A pregnancy test to exclude pregnancy will be performed for women of childbearing potential prior to recruitment~* Patients who are unable or unwilling to give written informed consent and to participate in and comply with the study protocol~* Presence of systemic infection or malignancy requiring therapy at the time of entry to the study~* Patients simultaneously participating in another study or who have participated in another study within the last 30 days of entry into this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): MMF
- 2 (Type: ACTIVE_COMPARATOR): Control

Based on this trial design, predict the completion outcome and termination type (if applicable).